Locally Advanced Malignant Solid Neoplasm: Clinical Trials

17 trials for Locally Advanced Malignant Solid Neoplasm, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 active not recruiting, 5 recruiting, 2 completed, 2 terminated. 17 Phase 2, 5 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 217Active not recruiting 6, Recruiting 5, Completed 2, Terminated 2, Not yet recruiting 1, Withdrawn 1
Phase 15Terminated 2, Active not recruiting 1, Completed 1, Recruiting 1

Follow Locally Advanced Malignant Solid Neoplasm: new trials by email Literature Review of Locally Advanced Malignant Solid Neoplasm trials Research Report on Locally Advanced Malignant Solid Neoplasm

Trials (filtered) newest first · largest first

All 17 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor
Trastuzumab Rezetecan - Solid Tumors, Neoplasms (Cancer / Tumors)
Phase 2Not yet recruitingHaihua Yuan152026-06-152026-06-08
Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial
Biopsy Procedure, Biospecimen Collection, Computed Tomography - Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Phase 2Active not recruitingNational Cancer Institute (NCI)332023-09-222026-08-24
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Alpelisib, Binimetinib, Biopsy Procedure - Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8
Phase 2RecruitingNational Cancer Institute (NCI)29002023-04-072026-11-12
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
Cyclophosphamide, Neoantigen Peptide Vaccine, Pembrolizumab - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Phase 1 / Phase 2RecruitingMayo Clinic1382022-03-312026-08-20
Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors
Larotrectinib Sulfate - Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Phase 2RecruitingM.D. Anderson Cancer Center132021-04-302026-10-07
CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma
Agonistic Anti-OX40 Monoclonal Antibody INCAGN01949, VLP-encapsulated TLR9 Agonist CMP-001 - Locally Advanced Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma
Phase 1 / Phase 2TerminatedUniversity of Southern California22021-04-292026-04-17
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
Biopsy Procedure, Biospecimen Collection, Computed Tomography - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8
Phase 2Active not recruitingNational Cancer Institute (NCI)292021-04-262026-11-12
Pevonedistat and Pembrolizumab for the Treatment of dMMR/MSI-H Metastatic or Locally Advanced Unresectable Solid Tumor
Pembrolizumab, Pevonedistat - Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Phase 1 / Phase 2TerminatedM.D. Anderson Cancer Center22021-03-292022-12-27
Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
Avapritinib - Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
Phase 2RecruitingM.D. Anderson Cancer Center502021-01-202026-06-11
Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies
Avelumab, Biopsy Procedure, Biospecimen Collection - Locally Advanced Malignant Solid Neoplasm, Locally Advanced Unresectable Cholangiocarcinoma
Phase 1 / Phase 2Active not recruitingNational Cancer Institute (NCI)1032020-04-072026-11-12
Pembrolizumab Before Surgery for the Treatment of Mismatch Repair Deficient Locally Advanced Solid Cancers
Pembrolizumab - Locally Advanced Malignant Solid Neoplasm
Phase 2CompletedM.D. Anderson Cancer Center352019-10-312025-05-13
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
Biopsy Procedure, Biospecimen Collection, Capecitabine - Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Phase 2RecruitingNational Cancer Institute (NCI)1152019-07-162026-11-12
Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers
Brigatinib, Laboratory Biomarker Analysis, Quality-of-Life Assessment - Advanced Malignant Neoplasm, ALK Fusion Protein Expression
Phase 2WithdrawnSameek Roychowdhury2019-03-202022-02-18
Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2
Adavosertib - Clear Cell Renal Cell Carcinoma, Locally Advanced Clear Cell Renal Cell Carcinoma
Phase 2Active not recruitingNational Cancer Institute (NCI)182019-01-292026-10-23
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
Ceralasertib, Olaparib, Durvalumab - Clear Cell Renal Cell Carcinoma, Locally Advanced Pancreatic Cancer
Phase 2Active not recruitingRahul Aggarwal832019-01-172026-04-23
Physical Activity With or Without Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Locally Advanced, Metastatic, or Recurrent Cancer
Dexamethasone, Exercise Intervention, Placebo Administration - Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid System Neoplasm
Phase 2Active not recruitingM.D. Anderson Cancer Center992018-06-292026-07-09
Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Biopsy, Biospecimen Collection, Computed Tomography - Hematopoietic and Lymphoid Cell Neoplasm, Locally Advanced Malignant Solid Neoplasm
Phase 1 / Phase 2CompletedNational Cancer Institute (NCI)272013-10-082025-01-14

Narrower conditions

Neoplasm Metastasis (15)  ·  Endometrial Neoplasms (4)  ·  Pancreatic Neoplasms (4)  ·  Carcinoma, Renal Cell (3)  ·  Carcinoma, Transitional Cell (3)  ·  Melanoma (3)  ·  Carcinoma, Non-Small-Cell Lung (2)  ·  Colorectal Neoplasms (2)  ·  Lung Neoplasms (2)  ·  Ovarian Neoplasms (2)  ·  Stomach Neoplasms (2)  ·  Uterine Cervical Neoplasms (2)  ·  Biliary Tract Neoplasms (1)  ·  Brain Neoplasms (1)  ·  Breast Neoplasms (1)

Broader conditions

Neoplasms (15)  ·  Neoplastic Processes (15)  ·  Pathologic Processes (15)  ·  Pathological Conditions, Signs and Symptoms (15)  ·  Neoplasms by Site (11)  ·  Digestive System Diseases (7)  ·  Digestive System Neoplasms (7)  ·  Neoplasms by Histologic Type (7)  ·  Female Urogenital Diseases (6)  ·  Female Urogenital Diseases and Pregnancy Complications (6)  ·  Urogenital Diseases (6)  ·  Urogenital Neoplasms (6)  ·  Carcinoma (5)  ·  Endocrine Gland Neoplasms (5)  ·  Endocrine System Diseases (5)

Interventions

Biopsy (7)  ·  Specimen Handling (7)  ·  Magnetic Resonance Spectroscopy (5)  ·  Paclitaxel (3)  ·  Taxes (3)  ·  pembrolizumab (3)  ·  Immunoglobulin G (2)  ·  durvalumab (2)  ·  ipatasertib (2)  ·  olaparib (2)  ·  130-nm albumin-bound paclitaxel (1)  ·  ADP Ribose Transferases (1)  ·  Albumin-Bound Paclitaxel (1)  ·  Alpelisib (1)  ·  CYT003-QbG10 (1)

Sponsors

National Cancer Institute (NCI) (7)  ·  M.D. Anderson Cancer Center (5)  ·  Haihua Yuan (1)  ·  Mayo Clinic (1)  ·  Rahul Aggarwal (1)  ·  Sameek Roychowdhury (1)  ·  University of Southern California (1)

Countries

United States (16)  ·  Puerto Rico (2)

Top investigators

A P Chen (2)  ·  Antoni Ribas (1)  ·  David S Hong (1)  ·  Diana L Hanna, MD (1)  ·  James M Ford (1)  ·  Jordi Rodon Ahnert (1)  ·  Kristen R Spencer (1)  ·  Michael J Overman (1)  ·  Michael J Overman, MD (1)  ·  Rahul Aggarwal, MD (1)  ·  Rahul R Aggarwal (1)  ·  Reva K Basho (1)  ·  Sameek Roychowdhury, MD (1)  ·  Sriram Yennu (1)  ·  Yanyan Lou, MD, PhD (1)

Results publications

PMID 33416261, PMID 36623241, PMID 38261444, PMID 38920407, PMID 39773433, PMID 41686845

NIH funding

U10CA180888 (2), P30CA014089 (1), P30CA016058 (1), R21NR016737 (1), U10CA032102 (1), U10CA180820 (1), U10CA180830 (1), UM1CA186644 (1), UM1CA186689 (1), UM1CA186716 (1), ZIABC011078 (1)